Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostate Cancer Metastatic × Pluvicto × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28 Metastatic Castration-resistant Prostate Cancer 3 Prostatic Diseases 2 Kidney Neoplasms 2 Carcinoma, Renal Cell 2 Urogenital Neoplasms 1 Thrombocytopenia 1 Prostate Cancer Metastatic 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Liver Neoplasms 1 Glioma 1 Glioblastoma 1 Genital Neoplasms, Male 1 Genital Diseases, Male 1 Disease 1 Cytopenia 1 Carcinoma, Hepatocellular 1 Astrocytoma 1 Anemia 1

Interventions

Radiosurgery 5 Androgen Antagonists 4 enzalutamide 2 Prednisone 2 Docetaxel 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 olaparib 1 gallium 68 PSMA-11 1 darolutamide 1 cabazitaxel 1 apalutamide 1 XRP6258 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 Hematologic Tests 1 Granulocyte Colony-Stimulating Factor 1 Gonadotropin-Releasing Hormone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡